Cross-Tapering Fluoxetine to Paroxetine

Introduction to Cross-Tapering Protocol

The American Academy of Child and Adolescent Psychiatry recommends initiating paroxetine immediately after discontinuing fluoxetine without a washout period, starting at a low dose of 10 mg daily and titrating slowly over several weeks while monitoring closely for serotonin syndrome 1, 2

The American Academy of Child and Adolescent Psychiatry suggests increasing paroxetine to 20 mg daily if well-tolerated, and continuing to monitor for serotonin syndrome symptoms such as confusion, agitation, tremors, clonus, hyperreflexia, muscle rigidity, and autonomic instability 1, 2, 3
The target dose of 40-50 mg may take 4-6 weeks to achieve safely, with increases of 10 mg every 1-2 weeks as tolerated, according to the American Academy of Child and Adolescent Psychiatry 1, 4, 5, 3

The American Academy of Child and Adolescent Psychiatry advises caution when combining two serotonergic drugs, even sequentially, due to the elevated risk of serotonin syndrome, particularly within 24-48 hours of dose changes 1, 2, 3
Monitoring for symptoms requiring immediate medical attention, including mental status changes, neuromuscular hyperactivity, autonomic hyperactivity, and advanced symptoms, is crucial, as recommended by the American Academy of Child and Adolescent Psychiatry 1, 2, 3
The American Academy of Child and Adolescent Psychiatry notes that paroxetine has the highest risk among SSRIs for discontinuation syndrome, characterized by dizziness, fatigue, sensory disturbances, paresthesias, anxiety, and agitation, although this is not a concern during the switch-in phase 1, 2, 4

Both fluoxetine and paroxetine are potent CYP2D6 inhibitors, which can significantly affect the metabolism of other medications, according to the American Academy of Child and Adolescent Psychiatry 1, 4
Reviewing all concurrent medications metabolized by CYP2D6 and considering dose adjustments of victim drugs with narrow therapeutic indices is essential, as recommended by the American Academy of Child and Adolescent Psychiatry 1, 4

The American Academy of Child and Adolescent Psychiatry warns against starting paroxetine at full therapeutic doses immediately, as this dramatically increases serotonin syndrome risk given fluoxetine's persistent effects 1, 2
Monitoring for suicidal ideation, particularly if the patient has comorbid depression, is crucial, as paroxetine has been associated with increased risk compared to other SSRIs, according to the American Academy of Child and Adolescent Psychiatry 1, 4